Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab plus tyrosine kinase inhibitor and chemotherapy for newly diagnosed Ph-positive or ABL-class Ph-like B-cell acute lymphoblastic leukemia
2025-520982-39-00Phase 3Authorised
- Sponsor
- University of Milano-Bicocca
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, open-label trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL) (3 cohorts), sponsored by University of Milano-Bicocca. Primary endpoints: 3-year event-free survival in Ph+ B-ALL, 3-year event-free survival in ABL-class Ph-like B-ALL and 1 more. Planned start Dec 2025; status: authorised.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2025-520982-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520982-39-00.